AstraZeneca's Imfinzi shows sustained benefit in lung cancer study [Reuters]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Reuters
AstraZeneca's Imfinzi shows sustained benefit in lung cancer study (Reuters) - AstraZeneca Plc said on Tuesday longer-term data from a late-stage trial on its cancer drug, Imfinzi, in combination with chemotherapies showed sustained improvement in overall survival of certain lung cancer patients, sending its shares up 4%. The results confirm a previous set of data from the same study, which was published in September and had led the U.S. Food and Drug Administration to give the drug a priority review status two months later. AstraZeneca has been trying to broaden the use of Imfinzi, which was the first immunotherapy to be approved for stage III lung cancer, by testing it as a standalone and a combo treatment for different forms of cancer. The study also tested the combination of Imfinzi with another immunotherapy, tremelimumab, as a first-line treatment in patients with extensive-stage small cell lung cancer, the company said. However, the treatment failed to meet the main goal of imp
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- My Green Lab Launches New Subsidiary for Enhanced Certification Impact [Yahoo! Finance]Yahoo! Finance
- [Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) [Yahoo! Finance]Latest
- Inhalation Capsules Market to Reach $1.5 Billion Globally by 2032 at 6.4% CAGR: Allied Market Research [Yahoo! Finance]Yahoo! Finance
- Nucleus RadioPharma Announces Appointment of Chris McDonald from Kite, a Gilead Company, to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Data from Brainomix's Collaboration with AstraZeneca Shows its AI-Powered e-Lung Better Identifies Lung Fibrosis Patients at Risk of Decline [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 3/25/24 - Form 6-K
- 3/19/24 - Form F-3ASR
- 3/19/24 - Form 6-K
- AZN's page on the SEC website